Clinical Trial

A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS)

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The study is designed to determine the efficacy and safety of roxadustat for the treatment of anemia due to very low, low, or intermediate risk MDS in participants with high transfusion burden (HTB).
Trial Details
NCT Number NCT07722988
Lead Sponsor Kyntra Bio
Conditions Myelodysplastic Syndromes
Enrollment 201 participants
Start Date 2027-04
Primary Completion 2030-09 (estimated)
Study Completion 2032-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-23